Phase II Trial of Erlotinib, a Small Molecule Tyrosine Kinase Inhibitor of EGFR, Prior to Surgery or Radiation in Patients With Aggressive Squamous Cell Cancers (SCC) of the Skin.

Trial Profile

Phase II Trial of Erlotinib, a Small Molecule Tyrosine Kinase Inhibitor of EGFR, Prior to Surgery or Radiation in Patients With Aggressive Squamous Cell Cancers (SCC) of the Skin.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Skin cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 May 2016 Status changed from completed to discontinued.
    • 03 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Mar 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top